Print Page   |   Contact Us   |   Sign In   |   Join iBIO
Industry News


TOP industry news from Business Wire

LifeArc, Dstl and CDRD Collaborate to Identify Antibacterial Drug TargetsOpen in a New Window

LONDON & PORTON DOWN, England & VANCOUVER, British Columbia--(BUSINESS WIRE)--#biotech--CDRD, LifeArc, and the UK Defence Science & Technology Lab are collaborating to fight antibiotic resistance and identify antibacterial drug targets.

 

PharmaCord Expands Leadership TeamOpen in a New Window

LOUISVILLE, Ky.--(BUSINESS WIRE)--PharmaCord LLC, an independently owned healthcare services company, expands leadership team.

 

Claritin® Featured on NBC’s ‘TODAY’ Show as No. 1 Pharmacist-Recommended Antihistamine (Allergy)Open in a New Window

WHIPPANY, N.J.--(BUSINESS WIRE)--Claritin® Featured on NBC’s ‘TODAY’ Show as No. 1 Pharmacist-Recommended Antihistamine (Allergy)

 

MetaStat Closes First Round of a $7 Million Private PlacementOpen in a New Window

BOSTON--(BUSINESS WIRE)--#breastcancer--MetaStat, Inc. (OTCQB:MTST), a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients, announced today it has consummated an initial closing of a private placement of up to $7 million of its common stock. The offering resulting in gross proceeds of approximately $2.14 million before placement agents’ fees and offering expenses was led by prominent institutional healthcare investor, Perceptive Advisors, LLC, along with

 

iBIO Institute’s PROPEL Center Celebrates 10 Years and Looks to Future with New Awards ProgramOpen in a New Window

CHICAGO--(BUSINESS WIRE)--#biotech--PROPEL celebrates 10 years and looks to future with new awards program; fundraising campaign to create SBIR/STTR Matching Awards for PROPEL startups.

 

Chondroitin Sulfate CS b-Bioactive® Proves Symptomatic Efficacy and Delays Knee Osteoarthritis ProgressionOpen in a New Window

BARCELONA--(BUSINESS WIRE)--#Bioiberica--Chondroitin sulfate CS b-Bioactive® (made by Bioiberica) delays osteoarthritis progression and is as effective as the anti-inflamatory drug celecoxib for improving the disease’s symptoms. These are the main conclusions of a new published clinical essay presented by Professor Jean Pierre Pelletier at the recent celebrated Annual European Congress of Rheumatology; being held in Madrid, Spain. The MOSAIC clinical essay (24 MOnth study on Structural changes in knee osteo

 

Spineology® Announces FDA Clearance of Rampart One™ Anterior Lumbar Interbody Fusion SystemOpen in a New Window

ST. PAUL, Minn.--(BUSINESS WIRE)--Spineology announces FDA clearance of the Rampart One Anterior Lumbar Interbody Fusion (ALIF) System.

 

PPD Appoints Experienced Industry Leader to Guide PPD® LaboratoriesOpen in a New Window

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD today announced it has appointed Christopher C. Fikry, M.D., as executive vice president of PPD® Laboratories.

 

Kite Named to the MIT Technology Review’s Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T TherapyOpen in a New Window

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, has been named to MIT Technology Review’s 2017 list of 50 Smartest Companies. To make the list, a company must exhibit technological leadership and business acumen which sets them apart from competitors. Kite was ranked #7 on this list for its leadership in establishing the field of engineered cell therapy for the treatment of cancer. “The companies on the list combine a high level of techno

 

Global Microbial Growth Media Market to Grow at a CAGR of 6.3% 2017-2021: Driven by High Demand for Improved Antibiotics - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Microbial Growth Media Market 2017-2021" report to their offering. The global microbial growth media market to grow at a CAGR of 6.36% during the period 2017-2021. Growth media is of great importance for microbiological tests; it helps obtain pure cultures, grow and count microbial cells, and cultivate and select microorganisms. High-quality growth media is important to achieve accurate and reproducible resu

 

AVEO Oncology Announces $14M in Aggregate Gross Proceeds from Hercules Credit Facility and At-the-market Stock OfferingsOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today announced that it has secured $14 million in aggregate gross proceeds through its credit facility with Hercules Capital, Inc. (Hercules) and the sale of common stock via its at-the-market issuance sales agreement with FBR & Co. (FBR). Pursuant to its 2010 loan and security agreement with Hercules, as amended in 2016, AVEO intends to draw down an additional $5 million in funding from Hercules and will defer the commencement

 

OrthoIndy Performs First Meniscus Replacements in Indiana with NUsurface® ImplantOpen in a New Window

INDIANAPOLIS--(BUSINESS WIRE)--The first meniscus replacement procedures using the NUsurface Implant have been performed in Indiana at OrthoIndy as part of the VENUS clinical trial.

 

Pfizer Breaks Ground on New R&D Facility in Chesterfield, MissouriOpen in a New Window

ST. LOUIS--(BUSINESS WIRE)--Today Pfizer Inc., (NYSE:PFE) one of the world’s premier biopharmaceutical companies, broke ground on a state-of-the art Research and Development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield, MO. The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the St. Louis area. Pfizer expects to hire an additional 80 employees over t

 

Cerulean Urges Stockholders to Vote for Proposals at July 19, 2017 Special Stockholder MeetingOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU) today urged stockholders of record at the close of business on June 9, 2017 to vote FOR all of the proposals at the upcoming special meeting of stockholders to be held on July 19, 2017. Each of the proposals is an important element of Cerulean’s plan to maximize stockholder value. On February 1, 2017, Cerulean announced its board of directors had initiated a review of strategic alternatives which could result in changes to its

 

Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary EndpointOpen in a New Window

JERUSALEM & BURNABY, British Columbia--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic neuralgia (PHN). TV-45070 did not meet the primary endpoint of a statistically significant change in pain from baseline to week four as assessed by the numeric rating scale (NRS). Secondary endpoints were also not met. There were no safety co

 

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion ProteinsOpen in a New Window

GENEVA--(BUSINESS WIRE)--Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that it has entered a commercial license agreement (CLA) that provides Takeda Pharmaceutical Company Limited [TSE:4502], (“Takeda”) with access to high-performance research cell banks (RCBs) developed using the Selexis SUREtechnology Platform™. Takeda is leveraging Selexis’ mammalian cell line-based protein expression platform to develop recom

 

Axial Biotherapeutics to Host Workshop Highlighting Advances in Gut Microbiome-Brain ConnectionsOpen in a New Window

BOSTON & PASADENA, Calif.--(BUSINESS WIRE)--Axial Biotherapeutics, a biotechnology company building a unique class of microbial-targeted CNS therapeutics, today announced that it will host a workshop at the Microbiome Drug Development Summit held in Boston Massachusetts, June 27-29, 2017. The workshop titled “Mind your gut: Harnessing the link between the human gut microbiome and the Central Nervous System to develop new therapeutics for neurological diseases” will be held on Tuesday, June 27 f

 

Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile InfectionOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Crestovo, a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota™ (FSM™) that harnesses the human gut microbiome, today announced that patients have been enrolling since the beginning of June in the company’s PRISM 3 clinical trial, evaluating its lead product candidate, CP101, for the prevention of recurrent Clostridium difficile infection (CDI). “We are pleased to have dosed patients in the PRISM 3 trial with CP101 as the leading cand

 

InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Thomas Jefferson University HospitalOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Thomas Jefferson University Hospital in Philadelphia, PA. James Harrop, M.D., Professor of Neurological and Orthopedic Surgery, Co-Director at the Delaware Valley Spinal Cord Injury C

 

Regenacy Pharmaceuticals Appoints Simon S. Jones as President and Chief Executive OfficerOpen in a New Window

BOSTON--(BUSINESS WIRE)--Regenacy Pharmaceuticals announced today the appointment of Simon S. Jones, Ph.D., as President and Chief Executive Officer.

 

NantCell, a NantWorks Company, to Acquire Altor BioScienceOpen in a New Window

CULVER CITY, Calif.--(BUSINESS WIRE)--NantCell, Inc., a member of the ecosystem of NantWorks companies, today announced that it has entered into a definitive merger agreement to acquire Altor BioScience Corporation. Under the terms of the merger agreement, each share of Altor BioScience capital stock will be converted into the right to receive an upfront payment of $2.00 (payable in cash and/or NantCell common stock at the election of each Altor BioScience stockholder). The upfront payment alon

 

DNAnexus Launches Novel Platform for Human Microbiome ResearchOpen in a New Window

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--#bigdata--Community-driven platform to advance microbiome bioinformatics and standards through global research and collaboration.

 

Les résultats de deux études pivots de phase lll portant sur l'émicizumab, l'anticorps bispécifique de Chugai, seront présentés à la réunion de l'ISTHOpen in a New Window

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé les résultats de deux études mondiales de phase lll portant sur l'émicizumab, l'anticorps bispécifique de Chugai (ACE910) : l'analyse primaire de l'étude HAVEN 1 (NCT02622321) et l'analyse intérimaire de l'étude HAVEN 2 (NCT02795767). Les données seront présentées le 10 juillet dans le cadre de la 26e réunion de l'International Society on Thrombosis and Haemostasis (ISTH) à Berlin, en Allemagne (du 8 au 13 juillet)

 

Bionext wprowadza Biosight, internetową platformę, która zrewolucjonizuje badania farmaceutyczneOpen in a New Window

STRASBURG, Francja--(BUSINESS WIRE)--spółka bioinformatyczna Bionext ogłosiła dzisiaj wprowadzenie BioSight, internetowej platformy biosymulacyjnej, która służy do sprawnej identyfikacji możliwych skutków ubocznych potencjalnych terapii farmakologicznych na ludzkie ciało. BioSight wykorzystuje opatentowany algorytm będący owocem 15 lat badań w dziedzinie biologii molekularnej, który potrafi przewidywać wszystkie cele biologiczne, w przypadku których występuje ryzyko interakcji z potencjalnymi t

 

TP Therapeutics Announces FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, or NTRK Oncogenic RearrangementsOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--TP Therapeutics: FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of NSCLC Adenocarcinomas Harboring ALK, ROS1, or NTRK Rearrangements

 

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA TherapeuticsOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--RaNA Therapeutics today announced the company has relaunched as Translate Bio.

 

Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNHOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced initial data from the Company’s global Phase 2 clinical program evaluating RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharma is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases and is developing RA101495 as a novel, subcutaneously-administered (SC) inhibitor of complement

 

Merck Provides Update on REVEAL Outcomes Study of AnacetrapibOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck Provides Update on REVEAL Outcomes Study of Anacetrapib

 

VarmX Raises Seed Capital for Development of Modified Blood Coagulation Factor XOpen in a New Window

LEIDEN, Netherlands--(BUSINESS WIRE)--VarmX gets seed financing for development of modified blood coagulation factor X, restoring blood clotting in patients using anticoagulants

 

Global Nerve Repair Biomaterials Market to Reach USD 775.6 Million by 2024: Analysis By Product Type, Injury Type, End User & Geography - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Nerve Repair Biomaterials Market - Trends and Forecast to 2024" report to their offering. The global nerve repair biomaterials market is witnessing a rapid growth due to increasing geriatric population, increasing incidence of nerve injuries and neurological disorders, favourable reimbursement policies, and increased government funding. The demand for nerve repair biomaterials is increasing in the hospitals

 

中外製藥在ISTH上呈報雙特異性抗體emicizumab的兩項樞紐性lll期研究結果Open in a New Window

東京--(BUSINESS WIRE)--(美國商業資訊) -- 中外製藥株式會社(TOKYO:4519)發表了該公司雙特異性抗體emicizumab (ACE910)的兩項全球性lll期研究結果:HAVEN 1研究(NCT02622321)的主要分析和HAVEN 2研究(NCT02795767)的中期分析。7月10日,上述資料將在即將(於7月8日至13日)於德國柏林召開的國際血栓暨止血學會(ISTH)第26次會議上呈報。上述研究受試者均為具有凝血因子的A型血友病患者,HAVEN 1為成人及青少年患者,HAVEN 2為兒童患者。 HAVEN 1 研究 研究描述 HAVEN 1為隨機、多中心、開放、全球性III期研究,評估 emicizumab每週一次皮下注射、療程24週或更長在具有第八凝血因子的A型血友病成人及青少年(12歲或以上)中的有效性、安全性、藥代動力學。 研究設計 n=109例 既往接受過繞徑藥物(Bypassing Agent,BPA)需要時治療的患者依2:1比例隨機分配至A組或B組         A組(n=35例):       Emicizumab每週一次給藥 B組

 

Genomics England adopte le logiciel BaseSpace d’Illumina pour le cancerOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc.(NASDAQ : ILMN) et Genomics England ont annoncé aujourd’hui qu’Illumina était le principal fournisseur de logiciels d’interprétation et de reporting de variantes et d’échantillons normaux appariés, dans le cadre du projet des 100 000 Genomes. Un peu plus d’un an après qu’Illumina ait annoncé la création avec Genomics England d’un partenariat en matière de bioinformatique et d’interprétation clinique, ce partenariat a maintenant défini des normes unifiée

 

Genomics England übernimmt BaseSpace Variant Interpreter für Krebs von IlluminaOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Illumina Inc. (NASDAQ: ILMN) und Genomics England haben heute bekannt gegeben, dass Illumina der Hauptanbieter von Software für die Interpretation von Tumorvarianten und für die Berichterstellung bei Tumorproben und übereinstimmende normale Proben ist, die im Rahmen des 100.000 Genomes Project beschrieben werden. In etwas über einem Jahr seit der Ankündigung der Partnerschaft mit Genomics England im Bereich der Bioinformatik und der klinischen Interpretation durch Il

 

Resumen: Chugai presentará los resultados de dos importantes estudios fundamentales de fase lll de su anticuerpo biespecífico emicizumab en el Congreso ISTHOpen in a New Window

TOKIO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) ha anunciado los resultados de dos estudios mundiales de fase lll para el anticuerpo biespecífico de Chugai, emicizumab (ACE910): el análisis primario del estudio HAVEN 1 (NCT02622321) y el análisis provisional del estudio HAVEN 2 (NCT02795767). Los datos se presentarán el 10 de julio en la 26 edición del Congreso ISTH (International Society on Thrombosis and Haemostasis) en Berlín (Alemania) que se celebra del 8 al 13 de juli

 

Samenvatting: Gegevens over bispecifiek antilichaam van Chugai uit cruciale fase III-onderzoeken gepresenteerd op ISTHOpen in a New Window

TOKIO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) heeft vandaag de resultaten van twee internationale fase III-onderzoeken naar zijn bispecifieke antilichaam emicizumab (ACE910) bekendgemaakt. Het gaat om een primaire analyse van het onderzoek HAVEN 1 (NCT02622321) en de tussentijdse analyse van HAVEN 2 (NCT02795767). De gegevens worden op 10 juli gepresenteerd op de 26e bijeenkomst van de International Society on Thrombosis and Haemostasis (ISTH) in Berlijn (8 tot 13 juli).

 

Ergebnisse von zwei Pivotstudien der Phase III mit dem bispezifischen Antikörper Emicizumab von Chugai werden am ISTH-Kongress vorgestelltOpen in a New Window

TOKIO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) hat die Ergebnisse von zwei globalen Studien der Phase III mit dem bispezifischen Antikörper Emicizumab (ACE910) von Chugai bekannt gegeben: die Primäranalyse der Studie HAVEN 1 (NCT02622321) und die Zwischenanalyse der Studie HAVEN 2 (NCT02795767). Die Daten werden am 10. Juli im Rahmen der 26. Tagung der Internationalen Gesellschaft für Thrombose und Hämostase (International Society on Thrombosis and Haemostasis, ISTH), vor

 

Mission Therapeutics Appoints Scientific Advisory BoardOpen in a New Window

CAMBRIDGE, England--(BUSINESS WIRE)--Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer, today announced the formation of its inaugural Scientific Advisory Board (SAB). Mission’s co-founder and CSO, Professor Steve Jackson, FRS, FMedSci will chair the SAB, where he will be joined by four independent, internationally r

 

Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2017Open in a New Window

NEW YORK--(BUSINESS WIRE)--Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2017

 

Résultats de l’Assemblée Générale Mixte des actionnaires de Cellectis S.A. du 26 juin 2017Open in a New Window

NEW YORK--(BUSINESS WIRE)--Regulatory News: L’Assemblée Générale mixte de Cellectis (Alternext : ALCLS – Nasdaq : CLLS) s’est tenue lundi 26 juin 2017 à Paris, au siège de la Société. À l’issue de l’Assemblée au cours de laquelle plus de 73 % des droits de vote se sont exprimés, l’intégralité des résolutions pour lesquelles le management a recommandé un vote en faveur, ont été adoptées. Les actionnaires de Cellectis avaient notamment à se prononcer sur : La nomination de deux nouveaux administr

 

bluebird bio Announces Proposed Public Offering of Common StockOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an underwritten public offering of $350 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public off

 

bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD)Open in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating Lenti-D™ investigational gene therapy in boys under 18 years old with cerebral adrenoleukodystrophy (CALD). “The hope that Lenti-D may

 

Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis (ISTH) CongressOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that new results from an ongoing Phase 2 open-label extension (OLE) study with the investigational therapeutic, fitusiran, in patients with hemophilia A and B, with or without inhibitors, will be presented in an oral presentation at the International Society of Thrombosis and Haemostasis (ISTH) Cong

 

Centrexion Therapeutics Names Shawn Tomasello to its Board of DirectorsOpen in a New Window

BOSTON--(BUSINESS WIRE)--Centrexion Therapeutics Names Shawn Tomasello to its Board of Directors

 

Lattice Biologics Ltd. Announces Move to Belgrade, MontanaOpen in a New Window

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) announces a relocation of its processing facilities to Belgrade, Montana. The relocation allows the Company to save over $80,000 per month in rents, overhead, wages and utilities. The new facility will enable the Company to focus on higher margin products and to develop processing automation needed to meet current orders. The relocation occurred on June 24th, 2017, and t

 

Riassunto: Genomics England adotta BaseSpace, la soluzione di Illumina per l'interpretazione delle varianti dei tumoriOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) e Genomics England hanno annunciato oggi che Illumina è il principale rivenditore di software di reportistica e interpretazione delle varianti per tumori e campioni normali caratterizzati nell'ambito del Progetto 100.000 genomi (100,000 Genomes Project). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono ri

 

3D Spheroid Culture Technology, 2016-2018 - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "3D Spheroid Culture Technology" report to their offering. This market report summarizes the results of an industry-wide global web-based benchmarking survey on three dimensional (3D) spheroid culture technology trends carried out in October 2016. The survey was initiated as part of our ongoing tracking of this rapidly emerging life science marketplace, and to update and extend the previous report entitled 3D Sphero

 

Sample Storage Quality & Identification Tracking Trends 2016 - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Sample Storage Quality & Identification Tracking Trends 2016" report to their offering. This market report summarizes the results of an industry-wide global web-based benchmarking survey on the emerging requirements for identification tracking and maintaining the quality of stored samples. The survey covered both biospecimens and drug compounds stored under frozen and/or ambient conditions. The survey was carri

 

Two Day Seminar: Life Science Accounting Update 2017 (San Jose, United States - September 21-22, 2017) - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Life Science Accounting Update 2017" conference to their offering. From technical accounting and revenue recognition new rules to cybersecurity and fraud, this conference will address the latest developments in key areas. You'll hear from experts at the Big Four and regional firms. Learning Objectives: - Understand the latest accounting changes in key areas - Recognize the timelines and key factors affecting the li

 

NeuroMetrix Provides Update on Quell Health Cloud Including Promotion of Dr. Xuan Kong to Chief Data ScientistOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--$NURO #NeuroMetrix--NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell® Health Cloud. Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning and artificial intelligence. The Quell device and its companion smartphone app connect seamlessly with the Quell Health Cloud. The cloud database stores the user’s demographic and clinical profile, health met

 

Award-winning Pediatric Dental Innovation Company Rebrands to Sprig Oral Health TechnologiesOpen in a New Window

LOOMIS, Calif.--(BUSINESS WIRE)--EZPEDO, the dental products company that invented the pediatric Zirconia crown, is now Sprig Oral Health Technologies (Sprig). The company has experienced strong growth over the last few years and today continues to develop and sell the market’s preferred pediatric Zirconia crowns —EZCrowns. Made from naturally occurring Zirconia, the revolutionary design of Sprig’s EZCrowns functions and appears like natural teeth while offering the best retention and ease-of-s
Association Management Software Powered by YourMembership  ::  Legal